http://medconferencestoday.com

Breaking Medical Conference News...

APA Resolves To Play Leading Role In Improving Treatment For Gender-Variant People

The American Psychological Association urged psychologists today to take a leading role in ending discrimination based on gender identity, calling upon the profession to provide "appropriate, nondiscriminatory treatment to all transgender and gender-variant individuals" and encouraging more research into all aspects of gender identity and expression.

Hearts A Flutter: Medical Students' Exams To Include Audio Portion For First Time

Hearts will be racing faster this fall for every medical student in the country. That's because the three-part test every medical student and resident must pass will be delivered in a new way: by listening to a heartbeat. It's a skill that some say has become an Achilles heel in the medical field. "Most of the doctors and residents out there taking this test know they don't have this auditory skill," says Michael Barrett, M.D.

$750,000 Grant To Rutgers College Of Nursing Awarded By F.M. Kirby Foundation

The F.M. Kirby Foundation of Morristown, N.J., awarded a $750,000 grant to the College of Nursing at Rutgers, The State University of New Jersey, to support the education of 10 doctoral fellows who are New Jersey residents. The grant will also fund the work of a faculty member who is committed to teaching, research and service in the best academic tradition, said Interim Dean Lucille Joel.

Over the past few years, CROs have received the lion's share of outsourced clinical research revenue.

CROs were first organized as outsourcing service companies that provided only clinical trial management. Today, many CROs have expanded their scope of services to provide comprehensive management of the complex drug trial processe
(613) 686-5745 Cerepotec Pharmalef

Senate Finance Committee Approves Two Bills To Help Prevent Neglect, Abuse Of Elderly Patients

The Senate Finance Committee on Wednesday by voice vote approved two bills that seek to prevent neglect and abuse of elderly patients, CQ Today reports. One bill (S 1070), sponsored by Sen. Orrin Hatch (R-Utah), would authorize $777 million to establish state and local training and assistance programs for long-term care employees.

New Grant Encourages Protected Research Time For Medical Fellows

The American Society of Hematology (ASH) is proud to announce the first recipients of the ASH Research Training Award for Fellows, a new program that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training. A report on the state of U.S.

Drexel University Online Launches Certificate In Medical Family Therapy

Drexel University Online is increasing its range of prestigious online healthcare programs with the addition of the Post-Master's Certificate in Medical Family Therapy. This 14 credit certificate is offered fully online. The certificate program is designed to introduce currently practicing health care professionals to the ways medical illnesses are influenced by external conditions and environments.

What the Title of Home-based Clinical Research Associate Really Means

The title of Clinical Research Associate is deceiving to some degree. Many people think of “associate” as a secondary low paying job. “Clinical Monitor” is a title that better describes what CRA job entails. A clinical research associate does not, in fact, assist anyone; the associate coordinates the smooth progress of a clinical trial.
(613) 686-5745 Cerepotec Pharmalef

AMSA Partners With Massachusetts Medical Society; Offers Members Discount To NEJM

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, announces its partnership with the Massachusetts Medical Society, owner and publisher of the New England Journal of Medicine (NEJM). Beginning today, AMSA student members will be eligible for a $52.00 annual subscription to the journal including online access to NEJM.org.

Virtual Student Support Via Second Life

The University of Houston department of health and human performance is expanding into the virtual world of Second Life (SL) thanks to grants from the UH Faculty Development Initiative Program (FDIP) and the Network Culture Project of the University of Southern California-Annenberg School for Communication. "These funds will allow our faculty to stake ground in Second Life for the benefit of our students and our community," said Charles Layne, professor and department chair.

New Book Dissects Statistics For Doctors And Medical Students

The medical literature is chock full of risk ratios, P values, numbers needed to treat, life tables, regressions, survival analyses, and confidence intervals. But what do they mean? A second edition of the book Medical Statistics Made Easy, recently released by Scion Publishing (http://www.scionpublishing.

Clinical outsourcing and current trends: How are they affecting business?

The clinical research industries growth is skyrocketing, the portion of the market outsourced to CROs is said to have grown from US$1 billion dollars in the early 1990’s to over US$17 billion in 2007.
(613) 686-5745 Cerepotec Pharmalef

Biologists, Educators Recognize Excellence In Evolution Education

The National Association of Biology Teachers (NABT) will recognize Dr. Randy Moore, a professor of biology at the University of Minnesota, with the 2008 Evolution Education Award during the NABT annual conference to be held 15-18 October 2008 in Memphis, Tennessee. The Evolution Education Award is cosponsored by the American Institute of Biological Sciences (AIBS) and the Biological Sciences Curriculum Study (BSCS).

Bi-Partisan Burgess Health Care Bills Headed To House Floor, USA

Congressman Michael C. Burgess, M.D. (R-TX) announced that two bi-partisan bills he helped write to improve health care passed out of committee and now head to the House floor. Votes are expected by the full House of Representatives in the next few weeks. The first bill, the Physician Workforce and Graduate Medical Education Enhancement Act (H.R.

Statement: GMC Welcomes Emphasis On Education And Training In Lord Darzi's Final Report Of The NHS Next Stage Review

Following a request from the Secretary of State for Health, Lord Darzi has conducted a wide-ranging review of the NHS, the final report of this review is launched. The General Medical Council is the independent regulator of the medical profession in the UK, with responsibility for regulating doctors' practice including overseeing undergraduate medical education and co-ordinating all stages of medical education and training.

The concept of outsourcing should not be new to pharmaceutical companies

The idea of outsourcing clinical trials took a dramatic increase two decades ago and continues to increase at a rapid pace.
(613) 686-5745 Cerepotec Pharmalef

Center For Dental Studies Successfully Completes $1M Grant Phase

The California Center for Advanced Dental Studies (CCADS) has successfully completed its first graduating class of doctors. Fifteen doctors from all over Northern California have completed a unique ten month educational program designed to advance their clinical skills in the area of cosmetic dentistry. Along with other recipients worldwide, educational grants in the amount of $18,500 were awarded to each doctor in this select group.

Virtual Reality Lab Enhances Surgeons' Skills

Virtual reality is making Dr. Angela Gucwa a better surgeon. Before she goes into the operating room, she spends several hours a week honing her skills in the Medical College of Georgia Virtual Education and Surgical Simulation Laboratory. "You become familiar with a lot of the different instruments," says Dr. Gucwa, a second-year surgical resident.

Many African-Americans Avoid Mammograms Due To Fear, Misconceptions About Screenings

Training physicians and caregivers to improve cultural sensitivity and communication with economically disadvantaged African-American patients could influence these women to get mammograms that could save their lives, according to a new study in the Journal of General Internal Medicine. The study found that many African-American women perceive they are being treated with disrespect and receive inadequate explanations about screenings when they go to health care facilities.

Ground breaking companies within the CRO industry

With over 1200 companies within the CRO industry Limdato www.limdato.com is one who is able to utilize cutting edge technology and innovations to ensure complete success for your clinical trial.
(613) 686-5745 Cerepotec Pharmalef

Physiotherapy Students Work Towards Developing The Patient Experience - University Of Bradford, England

Students from the School of Health Studies will be helping to improve the patient experience when they conduct assessments of patients at the University of Bradford on Tuesday, 11 November, 2008. The Physiotherapy students will work with patients from a local support group with the aim of the patients to feed back to inform the students what they did well and not so well.

Global Opportunities For Medical Students Recognised

The University of Queensland's School of Medicine has been recognised for its provision of innovative programs in outward mobility and student exchange. The School of Medicine won the Excellence in Outward Mobility award in the 2008 Queensland Education and Training International (QETI) awards last week.

New Program To Help Physicians Understand Role Of DNA-Based Preventive Medicine

American College of Preventive Medicine (ACPM) and Navigenics, Inc. today announced a medical education program designed to improve physicians' understanding of genetic risk factors for disease, the current evidence about the use of genomic tools and technologies to determine risk, and promising practices for utilizing those tools to aid in disease prevention.

Clinical Research Professionals are Still in Demand despite the World Economic Crisis

Despite the world economic crisis, the clinical research field is currently expanding faster than the introduction of newly qualified professionals that inevitably creates a demand. Most people are under the impression that the barriers to enter this industry are extremely difficult to overcome, but the truth is that everybody working in this industry had to start somewhere and as the industry grows positions need to be filled.
(613) 686-5745 Cerepotec Pharmalef

BMA Cymru Wales Welcomes Health Minister's Extension Of Free Accommodation For Junior Doctors

All first year doctors training in Wales will now benefit from free hospital accommodation until July 2010. Health Minister Edwina Hart had previously agreed to extend the provision of free on-site housing for F1 training grade doctors in Wales, until next Summer. She has now announced that will be extended for a further 12 months.

National Association Of School Nurses (NASN) Partners With Healthy Interactions To Advance Childhood Health Education

The National Association of School Nurses (NASN), the leader in advocacy for student health and the professional development of school nurses, and Healthy Interactions, a global leader in health education, today announced the beginning of a 5-year partnership.

Medical Students' Association Applauds National's Voluntary Bonding Scheme For Medical Graduates, New Zealand

The New Zealand Medical Students' Association (NZMSA) welcomed the announcement by John Key of the National party's Voluntary Bonding Scheme for medical graduates and other health professionals. The policy will provide debt relief to doctors choosing to stay in New Zealand.

US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril Derivatives

Cereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
(613) 686-5745 Cerepotec Pharmalef

Female Surgical Faculty May Be Increased By Improving University Recruitment Process, Study Finds

New research published in the June issue of the Journal of the American College of Surgeons shows that improving the university recruitment strategy and process could raise the number of women faculty in medicine. The study also suggests that specific procedural steps could assist in identifying and actively recruiting qualified women for faculty positions in surgery departments.

The AASM Will Actively Support IOM Recommendations That Both Enhance Patient Safety And Promote Quality Physician Training

The American Academy of Sleep Medicine (AASM) commends the Institute of Medicine of the National Academies (IOM) for its independent analysis of current duty-hour regulations for medical residents. The AASM will conduct a thorough review of the recommendations made in the IOM report, "Resident Duty Hours: Enhancing Sleep, Supervision, and Safety.

Plans For North Texas Region's First School Of Pharmacy - University Of Dallas Announces

The University of Dallas (UD) announced today its plans to develop North Texas' first professional doctor of pharmacy (Pharm.D.) degree program. The Dallas-Fort Worth Metroplex, the fourth-largest metropolitan area in the U.S., is the largest market in the country without an academic pharmacy program. The University expects to enroll its first class of 75 students in 2011. To spearhead this effort, the University has named renowned health sciences administrator and educator Dr.

Legal Issues in Clinical Research

Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization told in the interview to our edition that one hundred years ago, any doctor could prepare a new medication without any external approval.
(613) 686-5745 Cerepotec Pharmalef

Funding To Support Child Witness To Violence Project

Boston Medical Center has received a one-year grant for $50,000 from The Avon Foundation to support the Child Witness to Violence Project (CWVP) a counseling, advocacy and outreach program that focuses on young children who are bystanders to community and domestic violence. CWVP will use the grant to create a partnership to train police officers to better recognize and respond to children affected by violence.

Education Researchers Recommend Mobile Phone Ban In Schools Be Reassessed

Ask a teacher to name the most irritating invention of recent years and they will often nominate the mobile phone. Exasperated by the distractions and problems they create, many headteachers have ordered that pupils must keep their phones switched off at school. Others have told pupils to leave them at home.

Abstract Award Received By Bmc Nurse Manager

Hanover resident and Boston Medical Center (BMC) Nurse Manager Colleen LaBelle, RN, ACRN, CARN, was one of two semi-finalists to receive the Best Abstract Award from the Association for Medical Education and Research in Substance Abuse (AMERSA).

Anestvice Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery

Anestvice ( www.anestvice.com )Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery...
(613) 686-5745 Cerepotec Pharmalef

Tree Of Life Award Received By Jefferson Doctor

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently honored with a 'Tree of Life' award from The Wellness of You, a local nonprofit health education and resource organization. The Tree of Life award recognizes health professionals who are committed to making a difference in community health.

UNESCO Program To Help Teachers In Zimbabwe Access Drugs, Other Services

UNESCO plans to launch a network of HIV-positive teachers in Zimbabwe to help the group access no-cost antiretroviral drugs and other services, Zimbabwe's The Herald reports.

Plymouth Hospitals To Lead Cancer Surgery Training Programme, England

Plymouth Hospitals NHS Trust has been chosen to co-ordinate the national programme for the training of existing consultants in advanced keyhole surgery for the treatment of bowel cancer. The Department of Health has appointed Consultant General Surgeon, Mr Mark Coleman as the National Clinical Lead for the Laparoscopic Colorectal Cancer Surgery Training Programme.

Streamlining the process of Clinical Trials

The process of clinical trials can be costly to say the least. Clinical affairs consumes an average of 37% of R&D budgets.
(613) 686-5745 Cerepotec Pharmalef

Teaching Medicine In A Virtual Environment

Soon after students arrive at the University of Central Florida College of Medicine next fall, they likely will get a call in the middle of the night from a "virtual patient." The computer-generated patient will speak like a real human being complaining of ailments ranging from a common cold to cardiac arrest. How well students treat and advise their virtual patients on the spot will be a part of their evaluation.

Routes To Practicing Medicine - Association Of Faculties Of Medicine Of Canada

The majority of physicians practicing in Canada have gone through a similar education and examination process. Following an undergraduate experience outside of medicine (and for some, advanced degrees), completion of a four-year undergraduate medical education at an accredited Canadian faculty of medicine leads to the degree of Medical Doctor, the MD.

Deficits In Urological Knowledge Among Medical Students And Primary Care Providers: Potential For Impact On Urological Care

UroToday.com - Increasing attention is being directed to the urological education of medical students. Recently a decline in this teaching at the medical school level has raised concerns with regards to general clinician knowledge of clinical problems related to urology and to the recruitment of students to urology residency training.

Cereprotex displayed a significant anti-edema effect in a model of closed head injury.

Cereprotex displayed a significant anti-edema effect in a model of closed head injury. It significant decreases in the degree of edema developed after injury was found following treatment postponed one hour after traumatic injury..
(613) 686-5745 Cerepotec Pharmalef

Online Mentoring Scheme Aims To Support Pupils' Healthcare Studies, UK

A new scheme aimed at helping senior school pupils prepare for healthcare studies at college or university is launched this week (Friday 7 November). The 'WHAN Online Mentoring Scheme' links up pupils with students already studying on the courses they are interested in applying for. Mentoring is organised through a safe and secure dedicated website and monitored by project staff.

Medical Students Open Up To Epocrates

For the third consecutive year, future physicians speak out on the quality of medical training and failing healthcare system. Technology is also top of mind for today's medical students, who are seven times more likely to call on an electronic resource than a colleague or teacher with a medical question, and strongly support the use of electronic medical records in practice. Conducted by Epocrates, Inc.

Facial Expression Recognition Research To Make Robots More Effective Teachers

A computer science Ph.D. student can turn his face into a remote control that speeds and slows video playback. The proof-of-concept demonstration is part of a larger project to use automated facial expression recognition to make robots more effective teachers. Jacob Whitehill, a computer science Ph.D. student from UC San Diego's Jacobs School of Engineering, is leading this project.

Clinical outsourcing and current trends: How are they affecting business?

The clinical research industries growth is skyrocketing, the portion of the market outsourced to CROs is said to have grown from US$1 billion dollars in the early 1990’s to over US$17 billion in 2007.
(613) 686-5745 Cerepotec Pharmalef

Science 2008, Pitt's Eighth Annual Science Showcase, To Highlight Contemporary Research And New Technology

Science 2008, the University of Pittsburgh's eighth annual showcase of science and technology, will focus this year on how contemporary science can adapt the legacy of past achievements to meet future challenges in diverse disciplines for the benefit of generations to come. The two-day program will be held Oct. 2 and 3 in Alumni Hall, 4227 Fifth Ave., Oakland.

Nitric Oxide Measurement In Asthma Patients Not Beneficial For Treatment

In combination with conventional management and assessment of asthma patients, the measurement of exhaled nitric oxide (NO) does not improve clinical outcomes, according to an article released on September 19, 2008 in The Lancet. NO in exhaled air is a known biomarker of inflammation in the airway, but until now its role has been unclear in the clinical management of asthma.

Benefits And Applications Of Medical Simulation Examined By Rhode Island Hospital Simulation Center

Emergency medicine physicians and simulation experts from Rhode Island Hospital discuss the benefits of advanced medical simulation in five manuscripts appearing in the November 2008 issue of Academic Emergency Medicine (now available online). The articles describe how simulation centers, along with new portable simulation technology, offer unique training opportunities for dynamic, complex and unanticipated medical situations in acute care fields.

Patients enrolment is a greatest challenge for the clinical research industry in the USA, Canada and European Union.

Patients enrolment is a greatest challenge for the clinical research industry in the USA, Canada and European Union.
(613) 686-5745 Cerepotec Pharmalef

Key Role For Rural Practices In Helping Relieve Medical Training Pressures

The Federal Government must work urgently to better resource rural and remote general practices across Australia so they can help meet the increased demand for medical training being driven by the larger number of medical graduates coming from Australia's universities, the Rural Doctors Association of Australia (RDAA) argued today.

Initiatives, Events Offer Training To HIV/AIDS Workers, Educate Families On Children's Exposure To Toxins, Expand Services To American Indians

The following highlights initiatives and events that seek to reduce racial and ethnic health disparities.Denver: The National Native American AIDS Prevention Center is working with agencies to train public health workers in hopes of reducing the spread of HIV/AIDS among American Indians,

College Students In Georgia Work As Peer Educators To Raise HIV/AIDS Awareness Among Blacks

Students at Savannah State University are being trained as peer educators in an effort to increase awareness about the disproportionate impact of HIV/AIDS on young blacks in the U.S., the Savannah Morning News reports. Since 2005, a grant from the

Clinical Research Professionals are Still in Demand despite the World Economic Crisis

Despite the world economic crisis, the clinical research field is currently expanding faster than the introduction of newly qualified professionals that inevitably creates a demand. Most people are under the impression that the barriers to enter this industry are extremely difficult to overcome, but the truth is that everybody working in this industry had to start somewhere and as the industry grows positions need to be filled.
(613) 686-5745 Cerepotec Pharmalef

UNLV, NSC Partner On Effort To Improve Nurse Retention And Patient Care With Online Education

Nursing faculty at UNLV and Nevada State College (NSC) are collaborating to improve nurse retention and patient care in Nevada by expanding opportunities for registered nurses (RN) to earn a bachelor of science in nursing (BSN) through an online degree program. This is the first coordinated effort of its kind in Nevada and is being funded by a grant from the Health Resource and Services Administration (HRSA).

National Pathology Week 3-9 November - Royal College Of Pathologists

The Royal College of Pathologists and other specialist societies are holding the first National Pathology Week from 3-9 November 2008 to promote pathology. Over 150 fun free events are being held in hospitals and communities all over the United Kingdom and include interactive workshops, laboratory tours, stands in shopping centres, art competitions, quizzes and even a touring pathology bus.

AAMC Urges Congress To Stimulate The Economy Through Increased Support For NIH And Medical Education

The AAMC (Association of American Medical Colleges) called on Congress today to consider the role U.S. medical schools and teaching hospitals play in the nation's fiscal health as lawmakers develop legislation to stimulate economic recovery. In a recent letter to congressional leaders, the AAMC notes that medical schools and teaching hospitals have a substantial economic and social impact within the counties and cities they serve.

Professor Esther Shohami has joined the board of advisors of Cereprotec Incorporated

Professor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage...
(613) 686-5745 Cerepotec Pharmalef

American Medical Student Association Applauds Increase To National Health Service Corps

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, applauds the U.S. House of Representatives for passing the Health Centers Renewal Act (H.R. 1343), which reauthorizes the National Health Service Corps (NHSC) and increases its funding to over $185 million, an increase of more than 30 percent.

Washington Post Magazine Examines Medical Students' Decision Whether To Become Abortion Providers

The Washington Post Magazine on Sunday examined challenges medical students face when considering whether to become abortion providers. According to the Post Magazine, the number of abortion providers in the U.S. is declining, and "unless a new generation [takes] their place, the right to abortion might be rendered meaningless.

Public Open Day To Discover The 'hidden Science' Of Modern Medicine, Barts And The London NHS Trust And School Of Medicine And Dentistry

Barts and The London NHS Trust and School of Medicine and Dentistry, is welcoming visitors for a 'Pathology Open Afternoon' to unravel some of the mysteries surrounding pathology, the hidden science at the heart of modern medicine. On Wednesday afternoon, 5 November, visitors to the recently completed, state-of-the-art, Pathology and Pharmacy Building at The Royal London Hospital will have an opportunity to find out how pathologists diagnose common life-threatening disease.

Over the past few years, CROs have received the lion's share of outsourced clinical research revenue.

CROs were first organized as outsourcing service companies that provided only clinical trial management. Today, many CROs have expanded their scope of services to provide comprehensive management of the complex drug trial processe
(613) 686-5745 Cerepotec Pharmalef

GP Training Step A Must For Future Workforce, Australian Medical Association

The launch of 197 new GP training places over the next two years is a positive step towards securing the future of the general practice in Australia, the Australian Medical Students' Association (AMSA) said today. Health minister Nicola Roxon and Prime Minister Kevin Rudd today announced an extra 175 GP training places over two years and 22 extra places in the remote GP vocational scheme.

Preparing Physicians For Aging Baby Boomers' Needs In Hospice And Palliative Medicine

The American Academy of Hospice and Palliative Medicine announces two important medical education courses in hospice and palliative medicine and a significantly revised book series in keeping with the Academy's ongoing commitment to prevent and relieve pain and suffering during serious illness. Hospice and palliative medicine physicians have demonstrated a unique skill set that is highly appealing to patients and those who care for them.


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.

One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.

Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.

This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.

In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.

This company is also developing a family of other promising novel chemical compounds.

Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.

Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.

Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.

Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.

Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.

In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.

Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.

They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.

They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838

1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.

3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.

4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.

5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.

6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.

7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.

8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.

9. The method according to claim 8, wherein said head trauma injury is closed head injury.

10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.

11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.

12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.

13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.

14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.

15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.

16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.

17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.

18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.

20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.

21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.


Viev all previous articles...

Some Article Feeds provided by MedicalNewsToday.com

More Articles of interest...

Breakthrough Optical Technology To Assess Colon Cancer Risk, Accuracy

Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer. The study appears in the October 2008 issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

Does Persistent Perineal Impact Increase Likelihood Of LUTS And Sexual Dysfunction In Equestrians?

Bicycle riding has been reported to be related to male sexual dysfunction. Dr. Shaheen Alanee and colleagues from Minneapolis hypothesized that similar force impacts might be seen in equestrian sports. They sought to evaluate the effect of horseback riding on urinary symptoms and sexual dysfunction in men and women. Swimmers were used as a control group.

Ardea Biosciences Initiates Phase 1/2 Study Of RDEA119, Its Lead MEK Inhibitor, In Combination With Nexavar In Patients With Advanced Cancer

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that it has initiated a Phase 1/2 study of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, in combination with Nexavar, which is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

Limdato’s Grasp On Streamlining Clinical Trials

Limdato, www.limdato.com understands that executing a successful clinical trial requires a seamless coordination and communication with all individuals involved on levels on the trial
(613) 686-5745 Cerepotec Pharmalef

Suicide Prevention And Antidepressants

Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement. However, recent reports also suggest that antidepressants might, in some rare cases, actually worsen suicidal tendencies instead of alleviating them. As a consequence, research has intensified to clarify this issue, and regulatory authorities in many countries have reconsidered their cost-benefit ratio.

Australian Stroke Study: Research Could Save Lives And Millions Of Dollars

The Hunter Medical Research Institute (HMRI) Stroke Research Group has developed a system to fast track stroke treatment which could benefit thousands of Australian stroke patients and save millions of dollars annually. The system (called the Pre-hospital Acute Stroke Triage or PAST Protocol) reduces pre-hospital and emergency department delays to allow more stroke patients to receive brain saving thrombolysis or clot busting treatment within the three hour treatment window.

Morphotek(R), Inc. Expands Its Phase II Trial Site Selections In The European Union - Pancreatic Cancer Treatment

Morphotek, Inc., a subsidiary of Eisai Corporation of North America, announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 Phase II study. The study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine.

Clinproxy recommends that sponsors use their expertise in creating a budget within their means.

It is a reality that the development of pharmaceutical drugs is a very expensive task. Yet, these costs are necessary due to the substantial investment of both resources and time of the companies in question.
(613) 686-5745 Cerepotec Pharmalef

Flu Vaccination Investigated In PLoS Medicine

With the new flu season beginning, the open-access journal PLoS Medicine has released two studies related to influenza vaccination, each showing that the population burden of the flu can be decreased overall by increasing the number of people vaccinated. The flu vaccine is often recommended for specific groups of people who are at a higher risk of spreading or suffering from influenza in targeted vaccination programs.

For Relapsed Multiple Myeloma Patients Drug Combination Improves Or Stabilizes Disease

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment. Interim results of an ongoing clinical trial evaluating pomalidomide, a new immunomodulatory agent, combined with dexamethasone (pom/dex), were presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco.

Synthetic Moleculues Could Add Spice To Fight Against Cancer

Turning up the heat on the red tomato during processing has the potential to give the popular garden staple added disease-fighting power, Ohio State University research suggests. Scientists have found that lycopene molecules in tomatoes that are combined with fat and subjected to intense heat during processing are restructured in a way that appears to ease their transport into the bloodstream and tissue.

Why Clinical Research Companies Cannot Hire CRA’s Without Experience?

As per Bruce Kriger, CEO of Kriger Research Group International www.kriger.com , leading training institution and clinical research organization, there are three main reasons that actual experience is essential:
(613) 686-5745 Cerepotec Pharmalef

Schering Plough Provides Update On Boceprevir Clinical Development And Introduces Potent Next Generation Oral HCV Protease Inhibitor

Schering-Plough Corporation (NYSE: SGP) provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential.

Novelos Therapeutics Announces Presentation Of Positive Results In Ongoing Phase 2 Neoadjuvant Breast Cancer Trial

Novelos Therapeutics, Inc.

Eating Walnuts Slows Cancer Growth, Laboratory Study Finds

Snack-sized quantities of walnuts slow cancer growth in mice, reports a Marshall University pilot study published in the current issue of the peer-reviewed journal Nutrition and Cancer. Researcher W. Elaine Hardman, Ph.D., of Marshall's Joan C.

Legal Issues in Clinical Research

Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization told in the interview to our edition that one hundred years ago, any doctor could prepare a new medication without any external approval.
(613) 686-5745 Cerepotec Pharmalef


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.

One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.

Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.

This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.

In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.

This company is also developing a family of other promising novel chemical compounds.

Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.

Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.

Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.

Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.

Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.

In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.

Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.

They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.

They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838

1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.

3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.

4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.

5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.

6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.

7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.

8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.

9. The method according to claim 8, wherein said head trauma injury is closed head injury.

10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.

11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.

12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.

13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.

14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.

15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.

16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.

17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.

18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.

20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.

21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
HOME . ARTICLESMORE FEATURES .  CONTACT

613-686-5745 Clinical training is not a Scam, you should take training courses that are not a scam. Not a clinical trial scam for training in the clinical trail industry. Clinical Research Associate Courses maybe not a scam but not really a scam you learn alot about Clinic trials. Don't tell me its a scam as I think it does not work. Opinions of Clinical Training seem to say these courses are a scam. This is not truly a scam, scams are not good and clinical trails is not one of them. Take Clinical courses and you won't be scammed. Is Clinical Research Associates Training a scam? 613-686-5745

And a pair of them on 800notes.com. pharmaceutical company you hope to one day work for. Similar to comments bearing the same signature and left elsewhere, it includes talk of defamation, and “offensive or harassing content” removing this blog trinity includes a recruiting agency, a pharma company, and a school

INSTITUTIONS THAT OFFERS A PRACTICAL ORIENTED COURSE IN CLINICAL RESEARCH.ClinfoSource online GCP training courses WARN OF ONE INSTITUTE. STAY AWAY. they will help you find a job in India. certificates courses, numerous spelling and grammar mistakes. Looking for clinical research staff nation-wide to prepare and initiate clinical trials. report a fraud. report this scam. moving forward in their clinical trial as it was approved.Espoir and PharmAlef are a complete and utter fraud

qualified for any clinical trials-related positions, but we highly recommend you get a clinical trials certificate. QA experience: GMP, GLP and GCP certificate through the training and certification  programs accredited by the International Biopharmaceutical Association. Certificate form Kriger and Bachelor's degree in science and clinical research experience preferred. I am still interested in pursuing a career in clinical research. 613-686-5745

http://www.clinicaltoday.com/ . http://pharmaindustrytoday.com/ . http://www.medicaltrainingtoday.com/ . http://medicalnewspress.com . http://medicaldevicesnews.com . http://MedConferencestoday.com . http://regulatoryaffairstoday.com